Can you explain the indication, dosing regimen, contraindications, and alternative treatments for Ajovy (fremanezumab) in adult migraine prevention?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Ajovy (Fremanezumab) for Migraine Prevention

Indication

Ajovy is FDA-approved for the preventive treatment of migraine in adults, covering both episodic and chronic migraine. 1 The drug is a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide (CGRP), a key neuropeptide in migraine pathophysiology. 2

Recent guidelines strongly support its use: The 2024 VA/DoD guidelines provide a strong recommendation for fremanezumab (along with erenumab and galcanezumab) for prevention of both episodic and chronic migraine 3, while the 2025 American College of Physicians guideline includes it among recommended CGRP monoclonal antibodies for episodic migraine prevention. 4

Dosing Regimen

Two subcutaneous dosing options are available:

  • 225 mg monthly (single injection), OR
  • 675 mg quarterly (administered as three consecutive 225 mg injections on the same day) 11

Administration Details:

  • Route: Subcutaneous injection only into abdomen, thigh, or upper arm (avoiding tender, bruised, red, or indurated areas)
  • Preparation: Remove from refrigerator and allow to reach room temperature for 30 minutes before injection (do not use heat sources)
  • Timing: If a dose is missed, administer as soon as possible and resume scheduling from that date
  • Storage caveat: Discard if left at room temperature for 7 days or longer 11

The drug can be self-administered by patients/caregivers after proper training, or given by healthcare professionals. 1

Contraindications

Ajovy is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or any excipients, including:

  • Anaphylaxis
  • Angioedema 11

Warning on Hypersensitivity:

Hypersensitivity reactions (rash, pruritus, urticaria) occurred in clinical trials, typically within hours to one month after administration. Most were mild-to-moderate, but some required corticosteroid treatment or discontinuation. If hypersensitivity occurs, consider discontinuing Ajovy immediately and institute appropriate therapy. 11

Alternative Treatments

When fremanezumab is not tolerated or provides inadequate response, the treatment landscape offers multiple evidence-based alternatives organized by strength of recommendation:

Strong Recommendations (per VA/DoD 2024):

  • Other CGRP monoclonal antibodies: Erenumab or galcanezumab (same strong recommendation as fremanezumab for episodic/chronic migraine) 3
  • Angiotensin receptor blockers: Candesartan or telmisartan (strong recommendation for episodic migraine) 3

Weak/Conditional Recommendations:

  • Gepants: Atogepant (weak recommendation for episodic migraine prevention) 3
  • Antiseizure medications: Topiramate (for episodic and chronic migraine) or valproate (episodic migraine) 3
  • Beta-blockers: Propranolol 3
  • ACE inhibitors: Lisinopril (episodic migraine) 3
  • OnabotulinumtoxinA: For chronic migraine only (weak recommendation); suggested AGAINST for episodic migraine 3
  • Eptinezumab: IV CGRP antibody (weak recommendation for episodic/chronic migraine) 3

Traditional Options with Limited Evidence:

The 2025 ACP guideline notes that many traditional preventive medications (tricyclic antidepressants like amitriptyline, SSRIs/SNRIs) have been used historically, though evidence quality is generally low. 4

Clinical Efficacy Context

Fremanezumab demonstrates robust efficacy across difficult-to-treat populations:

  • Reduces monthly migraine days by approximately 4-5 days versus 2.5 days with placebo over 12 weeks 5
  • Real-world data shows even greater magnitude: reduction of 5.8 monthly migraine days at 1 month, with approximately 50% of patients achieving ≥50% reduction in migraine frequency within 3 months 6
  • Particularly effective in medication overuse headache: Works in patients with prior treatment failures, concomitant depression, and those overusing acute medications 78
  • Pediatric approval: Recently approved for children/adolescents aged 6-17 years weighing ≥45 kg for episodic migraine 9

Safety Profile:

Injection-site reactions are the most common adverse event (≥5%). Hepatic function abnormalities occurred in approximately 1% of patients. 5 Long-term safety data shows adverse event rates of 5% at 6 months and 7% at 12 months, with constipation being most frequently reported. 6

Key Clinical Pitfalls to Avoid

  1. Do not warm with heat sources (hot water, microwave) - allow natural room temperature warming only
  2. Do not use if cloudy, discolored, or contains particles upon inspection
  3. Do not co-administer with other injectables at the same site
  4. Monitor for hypersensitivity within the first month after each dose, as most reactions occur during this window
  5. For quarterly dosing, all three 225 mg injections must be given on the same day - not spread across the quarter 11

References

5
Research

Fremanezumab for the Preventive Treatment of Chronic Migraine.

The New England journal of medicine, 2017

Related Questions

What is Ajovy (fremanezumab), including its mechanism, indication, and dosing for migraine prevention?
Can Ajovy (fremanezumab) be administered every six weeks?
What are the complete medication contraindications for AJOVY (fremanezumab)?
Can Ajovy (fremanezumab) cause upper respiratory infection symptoms?
Which acute migraine medications can be safely taken with Ajovy (fremanezumab) for breakthrough attacks?
What patient details (age, symptoms, ocular or systemic conditions, and specific retinal problem) are needed to give a specific recommendation about the retina?
In a patient with fasting glucose ~600 mg/dL who is taking metformin 1000 mg twice daily and insulin glargine (Lantus) 18 units at bedtime with only a low‑dose sliding‑scale, what is the appropriate medium insulin dose?
What physical therapy program is appropriate for a patient with moderate (VAS 4‑5) left‑leg radicular pain and occasional left thigh pain?
Can Wegovy (semaglutide) cause bowel obstruction?
How long does glucagon‑like peptide‑1 (GLP‑1) clear from the body?
How should I manage persistent hypertension in a patient whose blood pressure remains high despite being on metoprolol 100 mg twice daily, amlodipine 10 mg daily, losartan 50 mg daily, and torsemide 40 mg daily?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.